The efficacy of quadrivalent HPV vaccine

January 01, 0001

The efficacy of quadrivalent HPV vaccine

This international group of researchers sought to evaluate the efficacy of the human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias, as well as anogenital warts (condyloma acuminata). They used dats from two international, double blind, placebo controlled, randomised efficacy trials of quadrivalent HPV vaccine (FUTURE I and FUTURE II) involving 17 622 women aged 16-26 years. The per protocol susceptible population was composed of enrollees who received all three vaccine doses, tested negative for the relevant vaccine HPV types at day 1 through month 7, and had no major protocol violations.

The researchers found: "In the per protocol susceptible population, vaccine efficacy against lesions related to the HPV types in the vaccine was 96% for cervical intraepithelial neoplasia grade I, 100% for both vulvar and vaginal intraepithelial neoplasia grade I, and 99% for condyloma. Vaccine efficacy against any lesion (regardless of HPV type) in the generally naive population was 30%, 75%, and 48% for cervical, vulvar, and vaginal intraepithelial neoplasia grade I, respectively, and 83% for condyloma."

The researchers concluded: "Quadrivalent HPV vaccine provided sustained protection against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18) and a substantial reduction in the burden of these diseases through 42 months of follow-up."

This study finds the quadrivalent HPV vaccine to by highly efficacious in preventing low grade neoplasia from the HPV types included in the vaccine.

For the full abstract, click here.

BMJ 341:c3493, 20 July 2010
© The FUTURE I/II Study Group 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. The FUTURE I/II Study Group. Correspondence to J Dillner: [email protected]

Category: B. Blood/Immune Mechanisms, X. Female Genital System, Breast. Keywords: human papillomavirus, HPV, quadrivalent vaccine, neoplasia, anogential warts, randomized controlled trial, journal watch.
Synopsis edited by Dr Paul Schaefer, Toledo, Ohio. Posted on Global Family Doctor 31 August 2010

Pearls are an independent product of the Cochrane primary care group and are meant for educational use and not to guide clinical care.